149 related articles for article (PubMed ID: 32196645)
1. Ponatinib-induced lamellar ichthyosis-like eruption.
Thakur V; Malhotra P; Lad D; Chatterjee D; Vinay K; Dogra S
Int J Dermatol; 2020 May; 59(5):e156-e157. PubMed ID: 32196645
[No Abstract] [Full Text] [Related]
2. Lamellar ichthyosis-like eruption associated with ponatinib.
Örenay ÖM; Tamer F; Sarıfakıoğlu E; Yıldırım U
Acta Dermatovenerol Alp Pannonica Adriat; 2016 Sep; 25(3):59-60. PubMed ID: 27695870
[No Abstract] [Full Text] [Related]
3. Ponatinib-induced lamellar ichthyosis-like drug eruption.
Byrne N; Forde K; Mcdonald S; Malladi R; Chan S
Eur J Dermatol; 2024 Apr; 34(2):236-238. PubMed ID: 38907571
[No Abstract] [Full Text] [Related]
4. Pityriasis Rubra Pilaris-Like Reaction Induced by a Tyrosine Kinase Inhibitor, the Ponatinib.
Mongereau M; Hillion B; Fouillard L; Boivin JF; Gaudron S
Am J Dermatopathol; 2021 May; 43(5):394-395. PubMed ID: 33264130
[No Abstract] [Full Text] [Related]
5. Ichthyosiform Reaction Related to Ponatinib Therapy.
Fernández-González P; Buendía-Castaño D; Saceda-Corralo D; Jaen-Olasolo P
Actas Dermosifiliogr (Engl Ed); 2019 Dec; 110(10):873-875. PubMed ID: 31493826
[No Abstract] [Full Text] [Related]
6. Ponatinib-induced ichthyosiform drug eruption: insights into acquired ichthyosis.
Xu H; Busam KJ; Mauro MJ; Markova A
Dermatol Online J; 2017 Oct; 23(10):. PubMed ID: 29469781
[TBL] [Abstract][Full Text] [Related]
7. Ponatinib-induced pityriasiform, folliculocentric and ichthyosiform cutaneous toxicities.
Alloo A; Sheu J; Butrynski JE; DeAngelo DJ; George S; Murphy GF; LeBoeuf NR
Br J Dermatol; 2015 Aug; 173(2):574-7. PubMed ID: 25736577
[No Abstract] [Full Text] [Related]
8. Pityriasis rubra pilaris-like eruption associated with the multikinase inhibitor ponatinib.
Jack A; Mauro MJ; Ehst BD
J Am Acad Dermatol; 2013 Nov; 69(5):e249-e250. PubMed ID: 24124847
[No Abstract] [Full Text] [Related]
9. Ponatinib-induced neutrophilic panniculitis.
Zhang M; Hassan KM; Musiek A; Rosman IS
J Cutan Pathol; 2014 Jul; 41(7):597-601. PubMed ID: 24602068
[TBL] [Abstract][Full Text] [Related]
10. Unexpected Success of Watch and Wait Strategy in a Ponatinib-Intolerant Patient With Chronic Myeloid Leukemia.
Engel NW; Constantin A; Fowlkes S; Assouline S
J Oncol Pract; 2016 Jun; 12(6):592-4. PubMed ID: 27246687
[No Abstract] [Full Text] [Related]
11. Ponatinib-induced widespread ichthyosiform eruption.
Derlino F; Barruscotti S; Zappasodi P; Brazzelli V; Vassallo C
J Eur Acad Dermatol Venereol; 2017 Dec; 31(12):e519-e521. PubMed ID: 28557248
[No Abstract] [Full Text] [Related]
12. Ichthyosiform eruption and facial erythema secondary to ponatinib therapy.
Munera-Campos M; Carrascosa JM; Quer A; Ferrándiz C
J Dtsch Dermatol Ges; 2020 Jul; 18(7):743-747. PubMed ID: 32589336
[No Abstract] [Full Text] [Related]
13. Fatal progressive cerebral ischemia in CML under third-line treatment with ponatinib.
Mayer K; Gielen GH; Willinek W; Müller MC; Wolf D
Leukemia; 2014 Apr; 28(4):976-7. PubMed ID: 24170029
[No Abstract] [Full Text] [Related]
14. The role of ponatinib in chronic myeloid leukemia in the era of treatment free remission.
Andrews C; Lipton J
Leuk Lymphoma; 2019 Dec; 60(13):3099-3101. PubMed ID: 31556337
[No Abstract] [Full Text] [Related]
15. Ponatinib (Iclusig) for CML and Ph+ ALL.
Med Lett Drugs Ther; 2013 Sep; 55(1424):71-2. PubMed ID: 25970013
[No Abstract] [Full Text] [Related]
16. Rechallenge of ponatinib in chronic myeloid leukaemia after hepatotoxicity.
Boo YL; Liam CCK; Toh SG; Lim SM
Hong Kong Med J; 2019 Apr; 25(2):162-163. PubMed ID: 30971509
[No Abstract] [Full Text] [Related]
17. Efficacy and safety of second-line ponatinib after failure of a single previous tyrosine kinase inhibitor for chronic myeloid leukemia patients in chronic phase.
Breccia M; Abruzzese E; Iurlo A; Gozzini A; Isidori A; Gangemi D; Pregno P; Alimena G
Haematologica; 2016 Jun; 101(6):e267-8. PubMed ID: 27252515
[No Abstract] [Full Text] [Related]
18. Phase II trial of ponatinib in patients with chronic myeloid leukemia resistant to one previous tyrosine kinase inhibitor.
Sanford D; Kantarjian H; Skinner J; Jabbour E; Cortes J
Haematologica; 2015 Dec; 100(12):e494-5. PubMed ID: 26341741
[No Abstract] [Full Text] [Related]
19. Heliotrope-like eruption mimicking dermatomyositis in a patient treated with imatinib mesylate for chronic myeloid leukemia.
Kuwano Y; Asahina A; Watanabe R; Fujimoto M; Ihn H; Tamaki K
Int J Dermatol; 2006 Oct; 45(10):1249-51. PubMed ID: 17040457
[No Abstract] [Full Text] [Related]
20. [Ponatinib-induced ichthyosiform eruption].
Sibaud V; Mouchel PL; Touhouche A; Huguet F; Bertoli S
Ann Dermatol Venereol; 2019 Oct; 146(10):661-663. PubMed ID: 31540674
[No Abstract] [Full Text] [Related]
[Next] [New Search]